Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 23Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Leukemia 9Leukemia, Myeloid, Chronic-Phase 7Recurrence 4Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Biphenotypic, Acute 1Hematologic Tumors 1Congenital Abnormalities 1Blast Crisis 1

Interventions

Tretinoin 27Arsenic Trioxide 27Cytarabine 20Cyclophosphamide 14Methotrexate 13Idarubicin 13Busulfan 11Filgrastim 10Etoposide 8fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 7Mercaptopurine 7Gemtuzumab 7Daunorubicin 7Radiotherapy 6Tacrolimus 5Mitoxantrone 5Clofarabine 5Vorinostat 4Topotecan 4Sorafenib 4Antilymphocyte Serum 4Mycophenolic Acid 3Granulocyte Colony-Stimulating Factor 3Bortezomib 3Azacitidine 3venetoclax 2tamibarotene 2sargramostim 2romidepsin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Promyelocytic, Acute × Homoharringtonine × Clear all
NCT00030355 2013-03-22

Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡